Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
XTLB
XTLB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
XTLB News
XTL Biopharmaceuticals Adjusts ADS Ratio to 1:400
Mar 20 2026
seekingalpha
XTL Biopharmaceuticals Ltd. Announces Change in ADS Ratio from 1:100 to 1:400, Effective March 25, 2026
Mar 20 2026
moomoo
XTL Biopharmaceuticals Faces Nasdaq Delisting Risk
Feb 27 2026
seekingalpha
XTL Biopharmaceuticals Faces Nasdaq Delisting Risk
Feb 27 2026
Newsfilter
XTL Biopharmaceuticals Faces Nasdaq Delisting Risk with $47,000 Equity Deficit
Jan 23 2026
seekingalpha
Sanofi Secures EU Approval for Teizeild, Demonstrating Significant Efficacy in Type 1 Diabetes
Jan 16 2026
NASDAQ.COM
Gelteq Ltd Reports 22% Bioavailability Increase in Cannabinoid Oral Gel, Shares Surge 50.1%
Jan 14 2026
Benzinga
XTL Biopharmaceuticals Acquires 85% of NeuroNOS for $1M and Up to $32.5M in Milestones
Jan 13 2026
stocktwits
Beyond Air (XAIR) Sells 85% of NeuroNOS for Up to $32.5 Million
Jan 13 2026
Benzinga
XTL Biopharmaceuticals Acquires 85% of NeuroNOS to Target Autism Treatment Market
Jan 13 2026
Globenewswire
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Targeting Autism Therapeutics Market
Jan 13 2026
NASDAQ.COM
XTL Acquires 85% of NeuroNOS for $32.5 Million to Target Autism Treatment
Jan 13 2026
Globenewswire
Baidu Inc Proposes Spinoff of Kunlunxin H Shares, Stock Rises 12.3%
Jan 02 2026
Benzinga
XTL Biopharmaceuticals Faces Nasdaq Delisting Risk, Must Regain Compliance in 180 Days
Dec 26 2025
Newsfilter
XTL Biopharmaceuticals Fails to Meet Nasdaq Minimum Bid Price Requirement
Dec 24 2025
Globenewswire
Vision Marine Technologies Stock Rises Over 10%; Check Out 20 Stocks Making Moves in Premarket Trading
Dec 01 2025
Benzinga
Show More News
